|
Synonyms: Avonex® | Rebif®
IFN-β1a (recombinant human) is an approved drug (FDA (1996), EMA (1997))
Compound class:
Peptide or derivative
Comment: Compared to the sequence of the endogenous peptide, IFN-β1a has a Gln to Cys substitution at position 17 and retains the Asn glycosylation site at position 80. Whilst the regular form of this peptide has to be injected 1-3 times/week, a PEGylated form (peginterferon beta-1a) is now available that requires less frequent administration (on a fortnightly basis).
|
| References |
|
1. Oliver BJ, Kohli E, Kasper LH. (2011)
Interferon therapy in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of the comparative trials. J Neurol Sci, 302 (1-2): 96-105. [PMID:21167504] |
